122 related articles for article (PubMed ID: 8529065)
21. DOPA metabolism in neuroblastoma.
Helson L; Johnson GA; Smith R
Med Pediatr Oncol; 1980; 8(4):317-22. PubMed ID: 6779102
[TBL] [Abstract][Full Text] [Related]
22. Mouse neuroblastoma clone N1E-115: a suitable model for studying the action of dopamine agonists of tyrosine hydroxylase activity.
Bräutigam M; Dreesen R; Flosbach CW; Herken H
Biochem Pharmacol; 1982 Apr; 31(7):1279-82. PubMed ID: 6124255
[TBL] [Abstract][Full Text] [Related]
23. Effects of ordinary meals on plasma concentrations of 3,4-dihydroxyphenylalanine, dopamine sulphate and 3,4-dihydroxyphenylacetic acid.
Eldrup E; Møller SE; Andreasen J; Christensen NJ
Clin Sci (Lond); 1997 Apr; 92(4):423-30. PubMed ID: 9176043
[TBL] [Abstract][Full Text] [Related]
24. Derivation of urinary dopamine from plasma dopa.
Zimlichman R; Levinson PD; Kelly G; Stull R; Keiser HR; Goldstein DS
Clin Sci (Lond); 1988 Nov; 75(5):515-20. PubMed ID: 3151165
[TBL] [Abstract][Full Text] [Related]
25. Dopaminergic abnormalities in hypertension associated with moderate renal insufficiency.
Kuchel OG; Shigetomi S
Hypertension; 1994 Jan; 23(1 Suppl):I240-5. PubMed ID: 8282367
[TBL] [Abstract][Full Text] [Related]
26. Initial urinary catecholamine metabolite concentrations and prognosis in neuroblastoma.
Laug WE; Siegel SE; Shaw KN; Landing B; Baptista J; Gutenstein M
Pediatrics; 1978 Jul; 62(1):77-83. PubMed ID: 683787
[TBL] [Abstract][Full Text] [Related]
27. Flow cytometry DNA ploidy analysis and catecholamine secretion profiles in neuroblastoma.
Abramowsky CR; Taylor SR; Anton AH; Berk AI; Roederer M; Murphy RF
Cancer; 1989 May; 63(9):1752-6. PubMed ID: 2702581
[TBL] [Abstract][Full Text] [Related]
28. A specific radioenzymatic assay for dihydroxyphenylalanine (DOPA). Plasma dopa may be the precursor of urine free dopamine.
Brown MJ; Dollery CT
Br J Clin Pharmacol; 1981 Jan; 11(1):79-83. PubMed ID: 6783056
[TBL] [Abstract][Full Text] [Related]
29. Dopa-release from mouse neuroblastoma clone N 1 E-115 into the culture medium. A test for tyrosine hydroxylase activity.
Bräutigam M; Dreesen R; Herken H
Naunyn Schmiedebergs Arch Pharmacol; 1982 Aug; 320(2):85-9. PubMed ID: 6126821
[TBL] [Abstract][Full Text] [Related]
30. Plasma 3,4-dihydroxyphenylalanine (dopa) and catecholamines in neuroblastoma or pheochromocytoma.
Goldstein DS; Stull R; Eisenhofer G; Sisson JC; Weder A; Averbuch SD; Keiser HR
Ann Intern Med; 1986 Dec; 105(6):887-8. PubMed ID: 3096183
[No Abstract] [Full Text] [Related]
31. Plasma levels of dihydroxyphenylalanine, dopamine and norepinephrine in the fetoplacental unit and maternal circulation at delivery.
Yamamoto K; Shirai T; Katoh S; Yasuda A; Kitao M
Nihon Sanka Fujinka Gakkai Zasshi; 1988 Dec; 40(12):1894-8. PubMed ID: 3145319
[TBL] [Abstract][Full Text] [Related]
32. Ascorbic acid stimulates DOPA synthesis and tyrosine hydroxylase gene expression in the human neuroblastoma cell line SK-N-SH.
Seitz G; Gebhardt S; Beck JF; Böhm W; Lode HN; Niethammer D; Bruchelt G
Neurosci Lett; 1998 Mar; 244(1):33-6. PubMed ID: 9578138
[TBL] [Abstract][Full Text] [Related]
33. Sympathoadrenal contribution to plasma dopa (3,4-dihydroxyphenylalanine) in rats.
Grossman E; Hoffman A; Armando I; Abassi Z; Kopin IJ; Goldstein DS
Clin Sci (Lond); 1992 Jul; 83(1):65-74. PubMed ID: 1325324
[TBL] [Abstract][Full Text] [Related]
34. Urinary excretion of dihydroxyphenylalanine and dopamine during alterations of dietary salt intake in humans.
Goldstein DS; Stull R; Eisenhofer G; Gill JR
Clin Sci (Lond); 1989 May; 76(5):517-22. PubMed ID: 2498027
[TBL] [Abstract][Full Text] [Related]
35. mRNAs of tyrosine hydroxylase and dopa decarboxylase but not of GD2 synthase are specific for neuroblastoma minimal disease and predicts outcome for children with high-risk disease when measured at diagnosis.
Träger C; Vernby A; Kullman A; Ora I; Kogner P; Kågedal B
Int J Cancer; 2008 Dec; 123(12):2849-55. PubMed ID: 18814238
[TBL] [Abstract][Full Text] [Related]
36. The neurochemistry of Parkinson's disease: effect of L-dopa therapy.
Lloyd KG; Davidson L; Hornykiewicz O
J Pharmacol Exp Ther; 1975 Dec; 195(3):453-64. PubMed ID: 489
[TBL] [Abstract][Full Text] [Related]
37. Metabolites of 6-[18F]fluoro-L-dopa in human blood.
Firnau G; Sood S; Chirakal R; Nahmias C; Garnett ES
J Nucl Med; 1988 Mar; 29(3):363-9. PubMed ID: 3126278
[TBL] [Abstract][Full Text] [Related]
38. Evaluation of neurotropic drug actions on tyrosine hydroxylase activity and dopamine metabolism in clonal cell lines.
Bräutigam M; Kittner B; Herken H
Arzneimittelforschung; 1985; 35(1A):277-84. PubMed ID: 2859029
[TBL] [Abstract][Full Text] [Related]
39. Hypothalamic secretion of dopamine after inhibition of aromatic L-amino acid decarboxylase activity.
Reymond MJ; Porter JC
Endocrinology; 1982 Oct; 111(4):1051-6. PubMed ID: 6811255
[TBL] [Abstract][Full Text] [Related]
40. The central aromatic amino acid DOPA decarboxylase inhibitor, NSD-1015, does not inhibit L-DOPA-induced circling in unilateral 6-OHDA-lesioned-rats.
Treseder SA; Rose S; Jenner P
Eur J Neurosci; 2001 Jan; 13(1):162-70. PubMed ID: 11135014
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
